Mei Pharma Appoints Biotechnology Executive Sujay Kango To Its Board Of Directors

The following excerpt is from the company's SEC filing.
SAN DIEGO, November 23, 2021 – MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer,
today announced the appointment of Mr. Sujay Kango to its board of directors effective November 22, 2021.
“We are very happy to welcome
Sujay, an industry leader with considerable commercialization and operational experience, to the MEI board as the company continues to exercise its vision to bring new therapies for cancer to patients,” said Christine A. White, M.D.,
chairman of the board, MEI Pharma. “As MEI prepares to transition to a commercial stage company , and grow its clinical pipeline, we greatly look forward to benefiting from the more than 25 years of industry insights and experience Sujay brings
to the company.”
“As MEI builds its capabilities to become a commercial stage company, I am eager to join the board of directors at this
important juncture to support the transformation,” said Sujay Kango. “I look forward to contributing to the growth of MEI, and its success as the company executes on its mission to deliver new therapies to patients with cancer.”

Mr. Sujay Kango is an experienced executive with more than 25 years of experience in the pharmaceutical and biotechnology industries. He has held
senior management positions where he has been instrumental in building commercial infrastructures and teams, while
leading multiple global product launches. He joined Acceleron Pharma in 2018, where he most recently served as the executive
vice president and chief commercial officer and was responsible for establishing the company’s North America commercial presence for luspatercept. Mr. Kango has additionally led multiple global product launches across several therapeutic
areas including oncology-hematology, rare diseases, immunology, and virology. Previously Mr. Kango was vice president of global commercial development for oncology at AbbVie, prior to which he served as the executive vice president and chief
commercial officer at Infinity Pharmaceuticals. Mr. Kango also served as vice president, global marketing, and sales operations at Onyx Pharmaceuticals, an Amgen subsidiary. Prior to Onyx, he held several leadership positions including vice
president sales and marketing-oncology at Merck & Co., global commercial leader-Procrit
/Eprex
at Ortho-Biotech, and various
sales and marketing positions at Schering-Plough. Mr. Kango earned a B.S. in Microbiology and an M.B.A. from McNeese State University.
The Company
also announced that after many years of service and dedication, Kevan Clemens, Ph.D., has resigned from the company’s board of directors and the compensation committee of the board of directors, effective November 22, 2021.
Dr. Clemens served as a member of the company’s board of directors since December 2014.
“We greatly appreciate and value the numerous
contributions Kevan has made to MEI during his years of service on the board of directors,” said Dr. White. “His industry and commercialization expertise have been invaluable to the growth and maturation of MEI and the development of
its pipeline of drug candidates.”
About MEI Pharma
MEI
Pharma, Inc. (Nasdaq: MEIP) is a late-stage pharmaceutical company focused on developing potential new therapies for cancer. MEI Pharma’s portfolio of drug candidates contains multiple clinical-stage assets, including zandelisib, currently in
ongoing clinical trials which may support marketing approvals with the U.S. Food and Drug Administration and other regulatory authorities globally. Each of MEI Pharma’s pipeline candidates leverages a different mechanism of action
with the objective of developing therapeutic options that are: (1) differentiated, (2) address unmet medical needs and (3) deliver improved benefit to patients either as standalone treatments or in combination with other therapeutic
options. For more information, please visit 
www.meipharma.com
. Follow us on Twitter 
@MEI_Pharma
 and on 
LinkedIn
Forward-Looking Statements
Under
U.S. law, a new drug cannot be marketed until it has been investigated in clinical studies and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are
“forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in
the forward-looking statements, which are based on management’s current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs
and delays in the development and or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; the impact of the

COVID-19
pandemic on our industry and individual companies, including on our counterparties, the supply chain, the execution of our clinical development programs, our access to financing and the allocation of
government resources; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and
distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business
without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government
regulation; changes in industry practice; and
one-time
events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.
Contacts:
David A. Walsey
858-369-7104
investor@meipharma.com
Jason I. Spark
Canale Communications for MEI
619-849-6005
jason.spark@canalecomm.com

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever MEI Pharma makes a similar move, sign up!

Auto Refresh

Feedback